8-K: Theriva Biologics Announces Positive Preclinical Data for VCN-01 Combination Therapy in Pancreatic Cancer

Theriva Biologics reports preclinical data showing enhanced anti-tumor effects when combining their lead product candidate, VCN-01, with liposomal irinotecan in pancreatic cancer models.

Summary

• Theriva Biologics has released preclinical data demonstrating that combining their oncolytic adenovirus, VCN-01, with liposomal irinotecan shows enhanced anti-tumor effects in human pancreatic cancer models.
• The data suggests a synergistic effect between VCN-01 and topoisomerase I inhibitors, like liposomal irinotecan, potentially improving treatment efficacy for pancreatic cancer.
• In vitro studies showed increased viral protein expression in pancreatic cancer cell lines when exposed to topoisomerase I inhibiting chemotherapeutics.
• In vivo studies using human pancreatic mouse xenograft models showed that VCN-01 or liposomal irinotecan alone resulted in significant tumor growth inhibition compared to saline.
• The combination therapy of VCN-01 and liposomal irinotecan showed significantly reduced tumor growth compared to either treatment alone.
• qPCR analysis confirmed the presence of viral genomes in tumors, indicating ongoing transcriptional activity of VCN-01 after administration.

Sentiment

Score: 8

Explanation: The document presents positive preclinical data with a clear path forward for clinical trials, indicating a strong potential for future success. The synergistic effect of the combination therapy is a significant positive.

Positives

• The combination of VCN-01 and liposomal irinotecan shows a tolerable toxicity profile.
• The study suggests that the combination therapy may improve efficacy in treating human pancreatic cancer.
• The data supports the potential synergy of VCN-01 with first-line pancreatic cancer chemotherapy regimens.
• The company is progressing the VIRAGE Phase 2b trial evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer.

Risks

• The ability to generate clinical data that establishes a synergy between VCN-01 and first-line pancreatic cancer chemotherapy regimens is a risk.
• The company's product candidates must demonstrate safety and effectiveness, consistent with prior results.
• The ability to complete clinical trials on time and achieve the desired results and benefits is a risk.
• Obtaining regulatory approval for commercialization of product candidates is a risk.
• Acceptance of product candidates in the marketplace is a risk.
• The company's ability to maintain license agreements and patent estate is a risk.
• The company's ability to remain well financed is a risk.

Future Outlook

Theriva Biologics plans to leverage these findings and evaluate the combination of VCN-01 with additional first-line pancreatic cancer chemotherapy regimens, including NALIRIFOX and FOLFIRINOX, while continuing to progress the VIRAGE Phase 2b trial.

Management Comments

• Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, stated that the data suggests the combination of VCN-01 and topoisomerase I inhibitors may provide a synergistic antitumor effect.
• The company looks forward to evaluating the combination of VCN-01 with additional first-line pancreatic cancer chemotherapy regimens.

Industry Context

This announcement is relevant to the broader field of oncology and the development of novel cancer therapies, particularly in the area of oncolytic viruses and combination treatments. The focus on pancreatic cancer, a disease with high unmet need, is also significant.

Comparison to Industry Standards

• The use of oncolytic viruses in combination with chemotherapy is an area of active research in oncology.
• Companies like Amgen (Imlygic) and Oncolytics Biotech (Pelareorep) are also developing oncolytic virus therapies, but the specific combination with liposomal irinotecan is unique to Theriva's approach.
• The preclinical results showing significant tumor growth inhibition are comparable to other successful preclinical studies in the field.
• The company's ongoing Phase 2b trial is a key step in validating the clinical potential of VCN-01.

Stakeholder Impact

• Shareholders may view this data positively, potentially increasing the company's stock value.
• The positive results could lead to increased interest from potential partners and investors.
• Patients with pancreatic cancer may benefit from the development of this new treatment option.
• Employees may be motivated by the positive progress of the company's lead product candidate.

Next Steps

• The company will present the data at the ASGCT 27th Annual Meeting on May 10, 2024.
• Theriva Biologics plans to evaluate the combination of VCN-01 with additional first-line pancreatic cancer chemotherapy regimens.
• The company will continue to progress the VIRAGE Phase 2b trial evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel.

Key Dates

Keywords

VCN-01, pancreatic cancer, liposomal irinotecan, oncolytic adenovirus, combination therapy, tumor growth inhibition, preclinical data, ASGCT, chemotherapy, VIRAGE Phase 2b trial